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Mesenchymal stem cells (MSCs) derived from adult bone
marrow have emerged as one of the most promising stem
cell types for treating cardiovascular disease (Pittenger and
Martin, 2004). Although the therapeutic effect of MSCs has
been attributed to their differentiation into reparative or
replacement cell types (e.g., cardiomyocytes, endothelial
cells, and vascular smooth cells) (Minguell and Erices, 2006;
Zimmet and Hare, 2005), it remains to be established if the
number of differentiated cell types generated is therapeu-
tically relevant. Recent reports have suggested that some of
these reparative effects are mediated by paracrine factors
secreted by MSCs (Caplan and Dennis, 2006a; Gnecchi et al.,
2005, 2006; Schafer and Northoff, 2008). In support of this
paracrine hypothesis, many studies have observed that MSCs
secrete cytokines, chemokines, and growth factors that
could potentially repair injured cardiac tissue mainly
through cardiac and vascular tissue growth and regeneration
(Caplan and Dennis, 2006b; Liu and Hwang, 2005). This
paracrine hypothesis could potentially provide for a non-
cell-based alternative for using MSCs in treatment of
cardiovascular disease (Pittenger and Martin, 2004). Non-
cell-based therapies as opposed to cell-based therapies are
generally easier to manufacture and are safer as they are
nonviable.
We have previously performed an unbiased proteomic
analysis of a chemically defined medium conditioned by
highly expandable human ESC-derived MSC cultures (Lian et
al., 2007; Sze et al., 2007). We identified N200 proteins in
the secretion of these MSCs (Sze et al., 2007). Computational
analysis of the secretome predicted that collectively, the
secretome has the potential to repair injured tissue such as
in myocardial ischemia/reperfusion (MI/R) injury (Sze et al.,
2007). MI/R injury refers to cell death and functional
deterioration that occurs during reperfusion therapy to
restore blood flow and salvage cardiomyocytes at risk of
dying from ischemia in an acute MI (AMI) (Cannon et al.,
2000; Saraste et al., 1997). Therefore, the effectiveness of
reperfusion therapy can be greatly enhanced by preventing
reperfusion injury for which there is currently no treatment
(Knight, 2007). We tested the computational prediction of
tissue salvage during reperfusion injury in a pig and mouse
models of MI/R injury. An intravenous bolus administration of
MSC-CM just before reperfusion substantially reduced infarct
size in both pig and mouse models of MI/R injury by ~60 and
~50%, respectively (Timmers et al., 2008). There was also a
significant preservation of cardiac function and reduction of
oxidative stress as early as 4 h after reperfusion (Timmers et
al., 2008). However, the active component in the secretion
and the mechanism by which it mediates this fast-acting
effect on MI/R injury have not been elucidated.
It is obvious that the immediacy of this protective effect
precludes the relatively lengthy process of gene transcription
and tissue regeneration as part of themechanism. Also, many
of the secreted proteins are membrane and intracellular
proteins, and are not known to cross plasma membranes
readily. This suggests that if these proteins mediate the
cardioprotective effect, the mechanism underlying the
therapeutic effect of MSC secretion must involve a vehicle
that facilitates crossing of membranes, thus representing a
radical shift from our present understanding of MSC paracrinesecretion which is limited to extracellular signaling by
cytokines, chemokines, and growth factors. To better
understand the cardioprotective paracrine effects of MSCs,
we then systematically fractionated the MSC-CM using
membranes with different molecular weight cut off
(MWCO). Based on these fractionations, we demonstrated
that the cardioprotective activity was in a N1000-kDa MW
fraction (Timmers et al., 2008). This suggested that the
cardioprotective effect was mediated by large complexes
with a diameter of 50–100 nm.
Here we demonstrate that these large complexes are
exosomes. By improving our proteomic analysis, we extend-
ed our previously reported list of 201 secreted proteins to
739 proteins and observed the presence of many exosome-
associated proteins. Some of these proteins were in
detergent-sensitive complexes. These proteins can be
sedimented by ultracentrifugation together with the mem-
brane phospholipids. Size-exclusion fractionation by HPLC
and dynamic light scattering analysis revealed the presence
of a population of particles with a hydrodynamic radius (Rh)
of 55–65 nm. More importantly, this HPLC fraction reduced
infarct size in a mouse model of MI/R injury.
Results
Cardioprotective secretion contains
exosome-associated proteins that form multiprotein
complexes
To identify the active component, we had previously
fractionated the CM by ultrafiltration through membranes
with different MWCO. It was shown that CM filtered through a
membrane with MWCO of 1000 kDa was not protective in a
mouse model of MI/R injury (Timmers et al., 2008). However,
CM concentrated by 125 times against a similar membrane
was protective. We observed that after filtration through
filters with a MWCO smaller than 0.2 mm such as 100, 300,
500, or 1000 kDa, the filtered CM was not cardioprotective
(Fig. 1A). In contrast, CM concentrated against a 1000-kDa
membrane (Timmers et al., 2008) or a 100-kDa membrane to
retain particles N1000 or 100 kDa, respectively, was
cardioprotective (Fig. 1). These observations suggested
that the active fraction consisted of large complexes of
N1000 kDa or had a predicted diameter of 50–100 nm.
Consistent with this, visualization of the CM by electron
microscopy revealed the presence of spherical structures
with a diameter of 50–100 nm and the morphology of a lipid
vesicle (Fig. 1B). Based on this size range and morphology,
we postulated that the likely candidate was a secreted
phospholipid vesicle known as exosome (Fevrier and Raposo,
2004; Keller et al., 2006).
To test this, we first determined if the CM contained the
subset of proteins that are commonly found in exosomes such
as CD9, CD81, and Alix (Olver and Vidal, 2007). These
proteins were not present in our previous proteomic profiling
of the secretion (Sze et al., 2007). By making modifications
to our proteomics methodology, we extended our list of
proteins found in the MSC secretion from 201 to 739 proteins
(Supplementary Table 1). The computationally predicted
biological activities of this proteome suggested that the
secretion will have significant biological effects on cardiac
Figure 1 Cardioprotective properties of CM fractions. (A)
Saline, HEK293 CM, or different preparations of hESC-MSC CM
were administered to a mouse model of MI/R injury as described
under Materials and methods. The b1000, b500, b300, and
b100 kDa represented CM filtered sequentially with membranes
that had MWCO of 1000, 500, 300, and 100 kDa, respectively.
The N100 kDa represented CM concentrated 50 times against a
TFF membrane with MWCO of 100 kDa. The infarct size (IS) was
expressed as a fraction of the area at risk (AAR) in the left
ventricle. (B) Transmission electron microscopic picture of CM;
scale bar represents 500 nm.
Figure 2 Presence of large lipid complexes in CM. (A)
Coimmunoprecipitation of CD81, CD9, and Alix. After immuno-
precipitation of hESC-MSC CM with anti-CD81 or mouse IgG, the
immunoprecipitate (IP) and supernatant (S) were analyzed by
Western blot hybridization using antibody against CD9 and Alix.
(B) Size fractionation by ultrafiltration and ultracentrifugation.
CM was concentrated 5X using a membrane with MWCO of
500 kDa. The retentate and the unfiltered CM were then
ultracentrifuged at 200 000 g for 2 h. The supernatant and the
pellet were analyzed by Western blotting for the presence of
CD9. Lanes 1–3: Different protein amount of CM. Lanes 4 and 5:
The pellet (P) and supernatant (S) after ultracentrifugation of
unfiltered CM. Lane 6: Retentate (R) after filtration of CM
through a membrane with MWCO of 500 kDa. Lanes 7 and 8: The
pellet (RP) and supernatant (RS) after ultracentrifugation of
retentate. Lane 9: Filtrate (F) after filtration of CM through a
membrane with MWCO of 500 kDa. (C) Amount of cholesterol,
spingomyelin, and phosphatidylcholine in CM and in the pellet
after 200 000 g ultracentrifugation of the CM was assayed and
quantitated as picomole per microgram protein.
216 R.C. Lai et al.tissue injury and repair (Fig. S1). The subsets of exosome-
associated proteins CD9, CD81, and Alix were confirmed to
be present in the secretion by Western blot analysis (lane 1,
Fig. 2A). The MW of CD9 and CD81 was the expected 25 and
22–26 kDa, respectively. Consistent with our hypothesis that
the large complexes are exosomes, we observed that CD9
and Alix coimmunoprecipitated with CD81, suggesting that
these proteins were in a single complex (Fig. 2A).
A 24-kDa CD9 sediments at 200 000 g and is retained
by membrane with 500-kDa MWCO
As exosomes are routinely purified by ultracentrifugation
(Thery et al., 2006), we next determined if CD9 was
associated with a large complex that can be precipitatedby ultracentrifugation. The CMwas first fractionated through
a membrane (MWCO=500 kDa) into a N500-kDa retentate
fraction and a b500-kDa filtrate fraction followed by
ultracentrifugation of both fractions. The 24-kDa CD9 was
found in the N500-kDa retentate fraction and could be
precipitated by ultracentrifugation (Fig. 2B). CD9 was not
detected in the b500-kDa filtrate fraction. Consistent with
our exosome hypothesis, major plasma membrane phospho-
lipids such as cholesterol, sphingomyelin, and phosphatidyl-
choline were also precipitated by ultracentrifugation at
200 000 g for 2 h as evidenced by their enrichment in the
precipitate (Fig. 2C).
Figure 4 Trypsinization of CM. CM treated with either PBS or
lysis buffer was digested with trypsin and an aliquot was
removed at 0.5, 2, 10, and 20 min. A trypsin inhibitor, PMSF,
was then added to terminate the trypsinization reaction and the
aliquots were analyzed for the presence of CD9 and SOD-1 by
Western blot hybridization.
217MSCs secrete cardioprotective exosomesProteins in the CM are associated with phospholipid
membrane
As exosomes are phospholipid vesicles, they are known to have
a typical density range of 1.10 to 1.18 g ml−1 that could be
resolved on sucrose gradients (Raposo et al., 1996; Thery et
al., 2006).We therefore postulated that the flotation densities
of the putative exosome-associated proteins would be
different before and after release from such vesicles by a
detergent-based buffer. Therefore, CM or CM pretreated with
a detergent-based lysis buffer was fractionated on a sucrose
density gradient by equilibrium ultracentrifugation. The
fractions were analyzed for the distribution of CD9 and
CD81. Both CD9 and CD81 which coimmunoprecipitated (Fig.
2A) had a similar flotation density that was heavier than that
expected of proteins in their MW range (Fig. 3). Pretreatment
with a detergent-based cell lysis buffer decreased the
apparent flotation densities of CD9 and CD81 to that of
proteins in a similar MW range (Fig. 3). Our observations
demonstrated that the detergent-sensitive flotation densities
of proteins were consistent with their location in lipid vesicles.
Exosomal proteins are either membrane bound or
encapsulated
As many of the secreted proteins in the CM are known
membrane or cytosolic proteins, we investigated if these
proteins in the CM were also membrane bound or localized
within the lumen of the putative exosomes by limited
trypsinization. Membrane-bound proteins would expected
to be partially resistant whereas luminal proteins are
expected to be resistant to trypsinization. Treatment withFigure 3 Protein analysis of CM fractionated on a sucrose
gradient density. CM or CM pretreated with lysis buffer was
loaded on a sucrose density gradient prepared by layering 14
sucrose solutions of concentrations from 22.8 to 60% (w/v) in a
SW60Ti centrifuge tube and then ultracentrifuged for 16.5 h at
200 000 g, 4 °C, in a SW60Ti rotor. The gradients were removed
from the top and the density of each fraction was calculated by
weighing a fixed volume of each fraction. The fractions were
analyzed by Western blot analysis for CD9 and CD81 in CM (upper
panel) and pretreated CM (lower panel). The distribution of a
protein standardmolecular weightmarker set after fractionation
in a similar gradient is denoted at the bottom of the figure.a detergent-based lysis buffer would abrogate this resis-
tance. As expected, CD9, a membrane-bound protein was
susceptible to trypsin digestion and generated two detect-
able tryptic peptide intermediates (Fig. 4). In contrast, SOD-
1, a cytosolic protein was resistant to trypsin digestion.
Pretreatment of CM with a detergent-based cell lysis buffer
abolished the resistance of CD9 and SOD-1 to trypsin
digestion. The detergent-sensitive partial susceptibility of
CD9 and resistance of SOD-1 to trypsin digestion were
consistent with their localization in a lipid membrane and
lumen of an exosome, respectively.
Purification of a homogeneous population of
exosomes by HPLC fractionation
To demonstrate directly that the active cardioprotective
component in the secretion is an exosome, CM and
nonconditioned medium (NCM) were first fractionated by
size exclusion on a HPLC column (Fig. 5A).The eluent was
monitored by absorbance at 220 nm and then examined by
dynamic light scattering which has a hydrodynamic radius
(Rh) detection range of 1 to 1000 nm. The first four eluting
fractions in CM (F1–F4) were not present in the NCM and
therefore represented secretion from the hESC-MSCs. F1, the
fastest eluting fraction with a retention time of 12 min,
represented the fraction containing the largest particles in
the CM. The particles in F1 were sufficiently homogeneous in
size such that they could be determined by dynamic light
scattering to have a hydrodynamic radius (Rh) of 55–65 nm.
All other peaks contained particles that were too heteroge-
neous in size to be estimated by dynamic light scattering. F1
contained 4% of total protein input but contained ∼50% of
the CD9 in the input (Fig. 5B). Proteins were distributed
among F2, F3, and F4 fractions according to the principle of
size-exclusion fractionation such that larger proteins were
eluted first in F2 followed by the smaller proteins in F3 and
the smallest in F4 (Fig. 5C). In contrast, proteins in the F1
fraction had a MW distribution that spanned the entire MW
spectrum of F2, F3, and F4 (Fig. 5C). The proteins in the F1
fraction despite having a MW range of 20 to 250 kDa
Figure 6 Flotation densities of proteins in CM and HPLC-
purified F1 fraction were determined by fractionating CM and F1
onto a sucrose gradient density as described above. The 13
fractions for (A) CM and (B) F1 were separated on a SDS-PAGE and
then stained with silver. (C) To evaluate the distribution of
smaller proteins, the F1 was also assayed for CD9 (20 kDa) by
Western blot hybridization. Proteins in the N1.20 g/ml density
fractions were denatured proteins.
Figure 5 HPLC fractionation of CM. (A) HPLC fractionation and
dynamic light scattering of CM and NCM. CM and NCM were
fractionated on a HPLC using a BioSep S4000, 7.8 mm×30 cm
column. The components in CM or NCM were eluted with 20 mM
phosphate buffer with 150 mM NaCl at pH 7.2. The elution mode
was isocratic and the run time was 40 min. The eluent was
monitored for UV absorbance at 220 nm. Each eluting peak was
then analyzed by light scattering and signals as measured in
voltage are represented by solid triangles. The eluted fractions,
F1 to F8, were collected, their volumes were adjusted to 50% of
the input volume of CM, and an equal volume of each fraction
was analyzed for (B) the presence of CD9 by Western blot
hybridization. Lanes 1–3 were CM loaded at 2X, 1X, or 0.5X of
the volume loaded used for each of the fractions, F1 to F8 (lanes
4–11), and therefore represented the equivalent of 100, 50, and
25% input CM. (C) Equal volumes of F1–F8 were separated on a
SDS-PAGE and then stained with silver.
218 R.C. Lai et al.sedimented at a similar flotation density of 1.11–1.16 g/ml
(Fig. 6B) that was similar to that of CD9 in the CM (Fig. 3).
These features of the F1 fraction, i.e., the presence of
proteins with a wide spectrum of MW sizes and identical
flotation density, the exclusive presence of CD9, and a
homogeneous size, indicated that a homogeneous exosome
population was purified from the CM by HPLC fractionation.
When 0.4 μg of F1 protein was administered to a mouse
model of MI/R injury 5 min prior to reperfusion, the F1
fraction reduced infarct size to the same extent as 3 μg CM
protein (Fig. 7A). All animals in this study had the same
degree of endangered myocardium, as illustrated by similar
area at risk within the left ventricle (Fig. 7B).Paracrine effect was mediated through heart tissues
For elucidating the mechanism of this paracrine effect, an
important prerequisite is the identification of the target
tissues. Here we determine that the paracrine effect on MR/I
injury was a heart autonomous effect and was independent of
circulating cells including immune cells. Using an ex vivo
mouse Langendorff heart model of ischemia/reperfusion
injury, we observed that conditioned medium reduced
relative infarct size to the same extent as in a mouse model
(Fig. 8).
Discussion
The trophic effects of MSC transplantation on ameliorating the
deleterious consequences of myocardial ischemia have been
implicated in several studies (Caplan and Dennis, 2006a).
Transplantation of MSCs into ischemic myocardium has been
shown to induce several tissue responses such as an increased
Figure 7 Cardioprotective exosomes. A 0.4 μg F1 protein was
administered intravenously to a mouse model of MI/R injury
5 min before reperfusion. Infarct sizes (IS) as a percentage of the
area at risk (AAR) on treatment with saline (n=10), conditioned
medium from hESC-MSCs (n=6), and HPLC fraction (n=5) were
measured. Saline treatment resulted in 34.5±3.3% infarction.
CM treatment resulted in 21.2±2.6% infarction (P=0.022
compared to saline) and F1 fraction treatment resulted in 17.0±
3.6% infarction (P=0.004 compared to saline). (B) AAR as a
percentage of the left ventricle (LV), showing the amount of
endangered myocardium after MI/R injury. All animals were
affected to the same extent by the operative procedure,
resulting in 39.1±2.2% of AAR among the groups. Each bar
represents mean±SEM.
219MSCs secrete cardioprotective exosomesproduction of angiogenic factors and decreased apoptosis
(Tang et al., 2005). It was postulated that these responses
were better explained by secretion of paracrine factors than
by differentiation of MSCs. In this context, MSCs were shown
to secrete many growth factors and cytokines that haveFigure 8 Secretion reduced myocardial ischemia-reperfusion
injury ex vivo. Perfusion buffer containing 3.5 μg/ml CM was
used to perfuse mouse heart in an ex vivo mouse Langendorff
heart model of MI/R injury 5 min before reperfusion. Infarct
sizes (IS) as a percentage of the area at risk (AAR) on treatment
with PBS (n=4) and CM (n=4) were measured after 3 h
reperfusion. Langendorff_PBS treatment resulted in 49.3±5.3%
infarction. Langendorff_CM treatment resulted in 24.6±4.4%
infarction (Pb0.001 compared to Langendorff_PBS). As a
reference for comparison, the in vivo effects of saline and CM
on IS/AAR as described in Fig. 7 are also included.effects on cells in their vicinity. To date, many of these
studies have focused exclusively on proteins that are known to
be secreted. These proteins generally included cytokines,
chemokines, and other growth factors (Caplan and Dennis,
2006a). However, our unbiased proteomic profiling of proteins
in the secretion of MSCs revealed an abundance of membrane
and cytosolic proteins (Sze et al., 2007). This suggests that the
trophic effects of MSCs may not be mediated by soluble
growth factors and cytokines alone. This was underscored by
our observation that the cardioprotective effects of CM were
mediated by 50- to 100-nm complexes of N1000 kDa (Timmers
et al., 2008) and not small soluble proteins.
Based on the size of the complex, we postulated that the
cardioprotective complex in the CM was likely to be an
exosome. Exosomes are formed from multivesicular bodies
with a bilipid membrane (Fevrier and Raposo, 2004; Keller et
al., 2006). They have a diameter of 40–100 nm and are known
to be secreted by many cell types (Fevrier and Raposo, 2004;
Keller et al., 2006). Electron microscopy confirmed that the
CM contained lipid-like vesicles of about 50–100 nm in
diameter. The functions of exosomes are not known but they
are thought to be important in intercellular communications.
Although exosomes are known to have a cell-type-specific
protein composition, most carry a common subset of proteins
that included CD9, CD81, Alix, TSP-1, SOD-1, and pyruvate
kinase (Olver and Vidal, 2007). CD9 and CD81 are tetrapannin
membrane proteins that are also localized in the membrane
of exosomes. Consistent with the presence of exosomes, CM
contained coimmunoprecipitating complexes of CD81, CD9,
and Alix. Ultracentrifugation precipitated CD9 with phospho-
lipids and cholesterol, suggesting that the CD81, CD9, and
Alix complex was associated with a phospholipid vesicle. This
was confirmed by the detergent-sensitive flotation densities
of these proteins where we demonstrated that the flotation
densities of these proteins in the CM were that of phospho-
lipid vesicles and that detergent treatment which dissolved
phospholipid membrane altered the flotation densities of the
proteins. We further demonstrated that CD9 in the CM was a
membrane-bound protein while SOD-1 was localized within a
lipid vesicle by their respective partial and complete
resistance to trypsin degradation and the abrogation of this
resistance by detergent. Taken together, our observations
demonstrated that exosomes with a diameter of 50–100 nm
are present in the CM and are therefore the likely candidate
for the cardioprotective component in the CM. This was
confirmed when a HLPC-purified homogeneous population of
particles that had an enrichment of CD9 and a Rh of 55–
65 nm substantially reduced infarct size in a mouse model
of MI/R injury at a reduced protein dosage equivalent to
∼10% of the CM dosage. We further demonstrated using an
ex vivo mouse Langendorff heart model of MI/R injury that
this paracrine effect was a heart autonomous effect, and
was independent of circulating cells, such as immune cells or
platelets.
In summary, we have identified exosome as the cardio-
protective component in MSC paracrine secretion. This
involvement of exosomes represents a radical shift in our
current understanding of the paracrine effect of MSC
transplantation on tissue repair which hitherto has been
limited to cytokine, chemokine, or growth factor-mediated
extracellular signaling. It also highlights for the first time the
role of exosome as mediator of tissue repair. As lipid vesicles,
220 R.C. Lai et al.exosomes represent an ideal vehicle to effect an immediate
physiological response to repair and recover from injury
through the rapid intracellular delivery of functional
proteins. Recently, it was demonstrated that in addition to
proteins, microvesicles have the potential to mediate
intercellular transfer of genetic material (reviewed in
Quesenberry and Aliotta, 2008). Several tumor cell types
(Rosell et al., 2009; Taylor and Gercel-Taylor, 2008),
peripheral blood cells (Hunter et al., 2008; Valadi et al.,
2007), endothelial progenitor cells (Deregibus et al., 2007),
and embryonic stem cells (Ratajczak et al., 2006) have been
shown to secrete RNA-containing microvesicles. More impor-
tantly, these microvesicular RNA could be transferred to
other cells and translated in the recipient cells (Deregibus et
al., 2007; Ratajczak et al., 2006; Valadi et al., 2007). We also
recently demonstrated that the MSC-derived exosomes
described here also contained miRNAs and these miRNAs
were predominantly in the precursor form (Chen et al.,
2010). For reperfused ischemic myocardium, this feature of
rapid initiation of cellular repair through the intracellular
delivery of functional proteins and possibly RNA is particu-
larly critical as the time window for therapeutic intervention
is very narrow. We speculate that the involvement of
exosomes in cardioprotection may represent a general
function of exosomes in tissue repair. It is possible that
different cell types produce exosomes that are specific for
certain type of cells or injuries. If true, this novel tissue-
repair function of exosomes could potentially engender new
approaches to the development of biologics.
Materials and methods
Preparation of CM
The culture of HuES9.E1 cells and preparation of HuES9.E1 CM
were performed as described previously (Lian et al., 2007; Sze
et al., 2007). For the b100-, b300-, b500-, or b1000-kDa
preparations in Fig. 1, the CM was first concentrated 25X by
tangential flow filtration (TFF) using a membrane with a 10-
kDa MWCO (Sartorius, Goettingen, Germany) and then filtered
sequentially through membranes with MWCO of 1000 kDa
(Sartorius), 500 kDa (Millipore, Billerica, MA), 300 kDa
(Sartorius), and finally 100 kDa (Sartorius). All other CM and
NCM used were concentrated 25X or 50X by TFF using a
membrane with 10- or 100-kDa MWCO (Sartorius). The CM and
NCM preparations were filtered with a 0.2-μm filter before
storage or use.
Electron microscopy, antibody array assay,
protein analysis
Electron microscopy, antibody array assay, and protein
analysis were done using standard protocols; for details
please refer to Supplementary Materials and Methods.
LC MS/MS analysis
Proteins in 2ml of dialyzed CM or NCMwere analysis by LCMS/
MS using standard protocols with some modifications; for
details please refer to Supplementary Materials and Methods.Immunoprecipitation of exosome-associated
proteins
Dynabead M-280 sheep anti-mouse IgG (Invitrogen Corpora-
tion, Carlsbad, CA) was washed using 0.1% BSA/PBS before
incubation with mouse anti-human CD81 antibody for 2 h
with gentle shaking at room temperature. The dynabeads
were washed twice and incubated with CM with gentle
shaking for 2 h at room temperature. The supernatant was
then collected, and the dynabeads were gently washed twice
before PBS was added. The supernatant and the dynabeads
were denatured, resolved on 4–12% SDS-PAGE, and analyzed
by Western blotting.
Sucrose gradient density equilibrium centrifugation
To generate the sucrose gradient density for centrifugation,
14 sucrose solutions with concentrations from 22.8 to 60%
were prepared and layered sequentially in an ultracentrifuge
tube (Beckman Coulter Inc., CA) starting with the most
concentrated solution. CM was loaded on top before
ultracentrifugation for 16.5 h at 200 000 g, 4 °C in a
SW60Ti rotor (Beckman Coulter Inc.). After centrifugation,
13 fractions were collected starting from the top of the
gradient. The densities of each were determined by weighing
a fixed volume. For pretreatment with detergent-based lysis
buffer (Cell Extraction Buffer, Biovision, Mountain View,
CA), CM was incubated with an equal volume of the lysis
buffer containing protease inhibitors (Halt Protease Inhibitor
Cocktail, Thermo Fisher Scientific Inc., Waltham, MA) for
30 min at room temperature with gentle shaking. The protein
concentration of CM was quantified using the NanoOrange
Protein Quantification kit (Invitrogen Corporation) according
to the manufacturer's instructions.
Sphingomyelin, phosphatidylcholine, and cholesterol
assay
Cholesterol, sphingomyelin, and phosphatidylcholine concen-
tration in CM and pellet from the ultracentrifugation of CM at
200 000 g for 2 h at 4 °C was determined using commercially
available assay kits. Cholesterol was measured using the
Amplex Red Cholesterol Assay kit (Invitrogen Corporation),
sphingomyelin, and phosphatidylcholine were measured using
the Sphingomyelin Assay Kit and Phosphatidylcholine Assay Kit
(Cayman Chemical Company, Ann Arbor, MI) respectively.
Limited trypsinization of CM
CM was incubated with equal volumes of either PBS or lysis
buffer (Cell Extraction Buffer, Biovision, Mountain View, CA)
for 45 min at 4 °C with gentle shaking. Then 16 μl of 10×
trypsin (Invitrogen Corporation) was added and incubated at
37 °C with gentle shaking. An aliquot was removed at 30 s,
1 min, 5 min, and 20 min, and 1 μl of a 100 mM trypsin
inhibitor, PMSF (Sigma-Aldrich, St. Louis, MO), was added. The
mixture was denatured and analyzed byWestern blot analysis.
HPLC dynamic light scattering
The instrument setup consisted of a liquid chromatography
system with a binary pump, an auto injector, a thermostated
221MSCs secrete cardioprotective exosomescolumn oven and a UV-visible detector operated by the
Class VP software from Shimadzu Corporation (Kyoto,
Japan). The Chromatography columns used were TSK
Guard column SWXL, 6×40 mm and TSK gel G4000
SWXL, 7.8×300 mm from Tosoh Corporation (Tokyo,
Japan).The following detectors, Dawn 8 (light scattering),
Optilab (refractive index), and QELS (dynamic light
scattering), were connected in series following the UV-
visible detector. The last three detectors were from
Wyatt Technology Corporation (CA, USA) and were
operated by the ASTRA software. For details please refer
to Supplementary Materials and Methods.
MI and surgical procedure
All experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Pigs prepared by
the Institute of Laboratory Animal Resources and with prior
approval by the Animal Experimentation Committee of the
Faculty of Medicine, Utrecht University, the Netherlands.
The CM and the HPLC fraction 1 (F1) were tested in a mouse
model of MI/R injury. MI was induced by 30 min left
coronary artery (LCA) occlusion and subsequent reperfu-
sion. Five minutes before reperfusion, mice were intrave-
nously infused with 200 μl saline-diluted CM containing 3 μg
protein or HPLC F1 containing 0.4 μg protein via the tail
vein. Control animals were infused with 200 μl saline. After
24 h reperfusion, infarct size (IS) as a percentage of the
area at risk (AAR) was assessed using Evans’ blue dye
injection and TTC staining as described previously (Arslan
et al., 2010).
Mouse Langendorff heart model of ischemia/
reperfusion injury
For the mouse Langendorff heart model of ischemia/
reperfusion injury, mice were given heparin 50 IE subcuta-
neously. The suture was placed in vivo without placing the
knot. Hereafter, the heart was excised and aortic root was
canulated and perfused in the Langendorff setup. After
10 min recovery, the suture was tightened to induce
ischemia for 30 min. Just 5 min prior to reperfusion, the
perfusion buffer was changed for a second buffer contain-
ing 3.5 μg/ml MSC-CM. Reperfusion was allowed for 3 h
before Evans' blue dye injection and TTC staining for infarct
size assessment, as described previously (Arslan et al.,
2009).
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